Key Clinical trials of 2016 - Canadian Society of Hospital...
Transcript of Key Clinical trials of 2016 - Canadian Society of Hospital...
![Page 1: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/1.jpg)
Key Clinical Trials of 2016
Morgan Schultz, BScPharm, PharmDClinical Pharmacist, Misericordia Community HospitalCSHP 43rd Annual Banff SeminarMarch 18th, 2017
![Page 2: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/2.jpg)
Presenter Disclosure•Presenter’s Name: Morgan Schultz
•I have no current or past relationships with commercial entities
•Speaking Fees for current program: • I have received a speaker’s fee from CHSP for this learning activity
![Page 3: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/3.jpg)
Commercial Support Disclosure•This program has received no financial or in-kind support from any commercial or other organization
![Page 4: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/4.jpg)
Learning Objectives•For each clinical trial you should be able to: • Describe the background and purpose• Appraise the study design• Interpret the study results• Determine the strengths and limitations• Assess the information for potential to change your clinical
practice
![Page 5: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/5.jpg)
Trial One: FLAMECOPD
http://www.clipartkid.com/images/768/fire-fighter-clip-art-TVpnDD-clipart.png
![Page 6: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/6.jpg)
Case One•60 year old male presents to ER with increased dyspnea & increased sputum volume; no fever
• No pneumonia on CXR, diagnosed with third COPD exacerbation (AECOPD) in past year
•Admitted to Medicine, given:• Amoxicillin 1g PO tid x 7 days• Prednisone 50mg PO daily x 5 days• Influenza vaccination
Condition MedicationCOPD Tiotropium 18 mcg inhaled daily
Salbutamol inhaled prnHTN HCTZ 25 mg PO daily
![Page 7: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/7.jpg)
Following the proper management of his AECOPD, what would you suggest for chronic management?
a) Review inhaler technique, continue on tiotropium (LAMA) & salbutamol prn (SABA)
b) Change to LAMA + LABA + salbutamol prn
c) Change to LABA + ICS + salbutamol prn
d) Change to LAMA + ICS + LABA + salbutamol prn
LAMA (long-acting antimuscarinic antagonists)
LABA (long-acting beta2-agonists)
Steroid
Tiotropium Fortmoterol BudesonideAclidinium Salmeterol FluticasoneGlycopyrronium IndaceterolUmeclidinium Olodeterol
RxFiles
Go to: PollEv.com/morganschult061OR Text “MORGANSCHULT061” to 37607
![Page 8: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/8.jpg)
![Page 9: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/9.jpg)
Guidelines
Group Suggested TherapyGroup A bronchodilatorGroup B LABA or LAMA
LAMA+LABA if persistent symptomsGroup C LAMA
If further exacerbations:LAMA + LABA (preferred) OR LABA+ICS
Group D LAMA + LABAIf further exacerbations: LAMA+LABA+ICS
GOLD 2017CHEST 2015
CHEST 2015; 147 ( 4 ): 894 - 942 From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http://goldcopd.org.
![Page 10: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/10.jpg)
Past TrialsTorch INSPIRE
Patients • Current/former smokers• Moderate to severe COPD
• Current/former smokers• Severe to very severe COPD
Intervention/ Comparator
a) Salmeterol 50 mcg + fluticasone 500 mcg bid
b) Salmeterol 50 mcg bidc) Fluticasone 500 mcg bidd) Placebo
a) Salmeterol 50 mcg + fluticasone 500 mcg bid
b) Tiotropium 18 mcg once daily
Outcome Primary: death from any cause Primary: AECOPDResults No difference in mortality between
groupsNo difference in rate of AECOPD
N Engl J Med 2007;356:775-89. Am J Respir Crit Care Med. 2008 Jan 1;177(1):19-26
![Page 11: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/11.jpg)
NEJM 2016; 374:2222-34
Multicenter, double blind, double dummy, non-inferiority trial
![Page 12: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/12.jpg)
FLAME: Inclusion & ExclusionInclusion Criteria Exclusion Criteria40 years of age or older CHF NYHA III/IVCOPD with grade ≥2 on modified Medical Research Council scale (MMRCS)
AECOPD with antibiotics and/or systemic steroids in last 6 weeks
Post-bronchodilator FEV1 of 25-60% of predicted (moderate to very severe COPD per GOLD criteria)
Respiratory tract infection in last 4 weeks
Post-bronchodilator FEV1/FVC <0.70 Oxygen therapy >12 hours per dayAECOPD during previous year receiving systemic antibiotics, steroids, or both
Asthma
From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. http://goldcopd.org. NEJM 2016; 374:2222-34
![Page 13: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/13.jpg)
FLAMEBaseline Characteristics
•N = 3362
•65 years of age
•76% male
•56% using inhaled steroids at screening
•61% LAMA; 67% LABA
•40% current smokers
•75% Group D severity (high risk and high symptom burden)
Intervention
•Indacaterol 110 mcg (LABA) + glycopyrronium 50 mcg (LAMA) daily
•Salbutamol prn
VS
•Salmeterol 50 mcg (LABA) + fluticasone 500 mcg (ICS) twice daily
•Salbutamol prn
•Groups similar at baseline
NEJM 2016; 374:2222-34
![Page 14: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/14.jpg)
FLAME
• Mild: worsening symptoms >2 days; no steroids or antibiotics• Moderate: steroids, antibiotics, or both• Severe: Hospital admission/visit to ER + steroids, antibiotics, or both
Outcome DescriptorPrimary Annual rate of all COPD exacerbations (mild, moderate, and
severe)Secondary If non-inferior determine superiorityAdditional time to first AECOPD, first moderate or severe AECOPD, first
severe AECOPD, annual rate of moderate/severe AECOPD, health status, use of rescue medications
NEJM 2016; 374:2222-34
![Page 15: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/15.jpg)
FLAME: Primary OutcomeIndaceterol + glycopyrronium
Salmeterol + fluticasone
RR (95% CI)
Annual rateAECOPD
3.59 4.03 0.89 (0.83-0.96)p = 0.003
NEJM 2016; 374:2222-34
![Page 16: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/16.jpg)
FLAME: Secondary OutcomesIndaceterol +
glycopyrroniumSalmeterol + fluticasone
RR (95% CI) ARR NNT(1 year)
Annual rate severe AECOPD 0.15 0.17 0.87 (0.69-1.09) - NSS
Clinicallyimportant ↓ in SGRQ-C
49.2% 43.7% - 5.5% 18
NEJM 2016; 374:2222-34
![Page 17: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/17.jpg)
FLAME: Adverse EventsIndaceterol +
glycopyrroniumSalmeterol + fluticasone
Pneumonia 3.2% 4.8%Oral Candidiasis 1.2% 4.2%Influenza 2.1% 3.3%Mortality 1.4% 1.4%
NEJM 2016; 374:2222-34
![Page 18: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/18.jpg)
Trial Conclusion•Among patients with COPD who had a history of exacerbation during the previous year, indacaterol-glycopyrronium was consistently more effective than salmeterol-fluticasone in preventing exacerbations and was associated with no detectable increase in adverse events.
NEJM 2016; 374:2222-34
![Page 19: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/19.jpg)
Critical AppraisalStrengths Weaknesses
Large sample size, multicenter Did not assess for LAMA side effects (ex. dry mouth, urinary retention)
Randomized, double-blind, double-dummy No change in mortality
Patients, investigator staff, data analysts all blindedPer-protocol analysis appropriately completedPatient important primary outcome
NEJM 2016; 374:2222-34
![Page 20: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/20.jpg)
Bottom Line•Trial indacaterol + glycopyrronium prior to trying a steroid in patients with severe COPD
*In Alberta: formulary restricted in hospital, special authorization in community with Alberta Blue Cross
![Page 21: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/21.jpg)
Following the proper management of his AECOPD, what would you suggest for chronic management?
a) Review inhaler technique, continue on tiotropium (LAMA) & salbutamol prn (SABA)
b) Change to LAMA + LABA + salbutamol prn
c) Change to LABA + ICS + salbutamol prn
d) Change to LAMA + ICS + LABA + salbutamol prn
LAMA (long-acting antimuscarinic antagonists)
LABA (long-acting beta2-agonists)
Steroid
Tiotropium Fortmoterol Budesonide
Aclidinium Salmeterol Fluticasone
Glycopyrronium Indaceterol
Umeclidinium Olodeterol
RxFiles
Go to: PollEv.com/morganschult061OR Text “MORGANSCHULT061” to 37607
![Page 22: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/22.jpg)
![Page 23: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/23.jpg)
Trial Two: HOPE-3CV risk reduction
http://images.clipartpanda.com/hope-clipart-hope-rise.jpg
![Page 24: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/24.jpg)
Case Two•66 year old male presenting to family doctor’s office• CC: “my wife said I had to come in for an annual check
up”
•No current prescribed medications
•Non-smoker, no second hand smoke exposure
•No family history of Cardiovascular disease
•You quickly calculate his Framingham Risk Score:
•15 points = Intermediate risk
ParameterBlood Pressure 138/82 mmHgTotal cholesterolTriglyceridesHDL-CLDLApo-B
5.5 mmol/L1.6 mmol/L1.2 mmol/L3.3 mmol/L1 g/L
Fasting glucose 5.3 mmol/LSCr 88 umol/LWaist to hip ratio 0.94
http://www.ccs.ca/images/Guidelines/Tools_and_Calculators_En/Lipids_Gui_2012_FRS_BW_EN.pdf
![Page 25: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/25.jpg)
Case Two•You collect some additional lifestyle information:
•Walks dog for 30 minutes 3x/week
•States several periods of stress in last year (lost job)
•Has meat two meals/day, fruit 2x/day, doesn’t like vegetables, has chips/salty snack every night before bed
•This allows you to calculate his Interheart score:
•13 points = Intermediate risk
https://rome.phri.ca/interheartriskscore
![Page 26: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/26.jpg)
With your APA – what would you prescribe?
a) Nothing – no indication to prescribeb) A statinc) A blood pressure agentd) Both a statin and a blood pressure agent
Go to: PollEv.com/morganschult061OR Text “MORGANSCHULT061” to 37607
![Page 27: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/27.jpg)
![Page 28: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/28.jpg)
Background• Benefit of treatment of HTN to reduce CV events in high risk patients has been found• Sprint – high CV risk (no diabetes)• HOPE – high CV risk or diabetes & CV risk factor
• Benefit of treatment of dyslipidemia for primary prevention with statins has been found• CARDS – Diabetes & ≥ 1 CV risk factor• JUPITER – 50% moderate CV risk patients
RxFilesN Engl J Med 2015;373:2103-16.N Engl J Med 2000;342:145-53.Lancet. 2004 Aug 21 27;364(9435):685-96N Engl J Med 2008; 359:2195-2207
![Page 29: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/29.jpg)
NEJM 2016. 374(21):2032-2343
Multicenter, double blind, 2x2 factorial, RCT
![Page 30: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/30.jpg)
HOPE-3: Inclusion & ExclusionInclusion Criteria Exclusion CriteriaMen ≥55, women ≥65 with one risk factor, or women ≥60 with two risk factors:
Cardiovascular disease
• Elevated waist-to-hip ratio• History of low level of HDL• Current/recent tobacco use,• Dysglycemia/impaired glucose tolerance• family history of premature coronary disease• mild renal dysfunction
Indication for/contraindication to: statins, ACEi, ARB, thiazidesSymptomatic hypotensionChronic liver diseaseModerate renal dysfunctionInflammatory muscle disease
NEJM 2016. 374(21):2032-2343
![Page 31: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/31.jpg)
HOPE-3: Baseline Characteristics•N = 12,705
•66 years of age
•54% male
•Mean BMI 27.1 (overweight)
•Mean SBP 138.1 mmHg
•Median fasting glucose 5.3 mmol/L
•INTERHEART risk score 14.5 (moderate risk)
•Risk factor for trial eligibility:• Elevated waist-to-hip ratio 86.8%• Low HDL-C 36.1%• Recent/current smoking 27.7%
NEJM 2016. 374(21):2032-2343
![Page 32: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/32.jpg)
Intervention
Rosuvastatin 10mg Placebo
Candesartan/HCTZ16mg/12.5mg 3180 3176
Placebo 3181 3168
NEJM 2016. 374(21):2032-2343
![Page 33: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/33.jpg)
HOPE-3: OutcomesOutcome DescriptorPrimary (composite)
Death from CV causes, nonfatal MI, or nonfatal stroke
Second co-primary Above + resuscitated cardiac arrest, heart failure, revascularizationSecondary Above + angina with evidence of ischemiaAdditional Death from any cause, individual components of above, new onset
diabetes, cognitive function, erectile dysfunction
NEJM 2016. 374(21):2032-2343
![Page 34: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/34.jpg)
HOPE-3: Primary Outcome
•Rosuvastatin alone vs candesartan/HCTZ alone• NSS difference between the two in primary• HR 0.82 (0.65-1.05)
• Co-primary 4.4% in rosuvastatin vs 5.5% in candesartan/HCTZ• HR 0.79 (0.64-0.99) SS
Combination Placebo HR (95% CI) NNT (5.6 years)
Primary 3.6% 5% 0.71 (0.56-0.90)p= 0.005 72
Co-primary 4.3% 5.9% 0.72 (0.57-0.89)p= 0.003 63
NEJM 2016. 374(21):2032-2343
![Page 35: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/35.jpg)
HOPE-3: Secondary Outcomes
•Average BP lowered by 6.2/3.2 mmHg in combination group
•Mean LDL lowered 0.87 mmol/L in combination group
NEJM 2016. 374(21):2032-2343
Combination Placebo HR (95% CI) NNT (5.6 years)Death 5.1% 5.6% 0.91 (0.73-1.12) NSS
Death CV causes 2.4% 2% 0.82 (0.60-1.11) NSS
![Page 36: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/36.jpg)
HOPE-3: Adverse Effects
NEJM 2016. 374(21):2032-2343
Combination Candesartan/HCTZ Rosuvastatin Placebo
Muscle pain & weakness 0.8% 0.8% 0.8% 0.7%Dizziness, light-headedness,
hypotension 2.1% 1.9% 1.3% 0.7%
![Page 37: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/37.jpg)
Other Portions of Trial: Rosuvastatin
Outcome Rosuvastatin Placebo HR (95% CI) NNT (5.6 years)
Primary 3.7% 4.8% 0.76 (0.64-0.91)p= 0.002 91
Co-primary 4.4% 5.7% 0.75 (0.64-0.88)p< 0.001 73
NEJM 2016;374:2009-20.
![Page 38: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/38.jpg)
Other Portions of Trial: Candesartan/HCLZ
•Only benefit in upper 3rd of blood pressure (SBP>143.5 mm Hg)• pre-specified subgroup
NEJM 2016;374:2021-31.
Candesartan/HCLZ Placebo HR (95% CI) NNT (5.6 years)Primary 4.1% 4.4% 0.93 (0.79-1.10) NSS
Co-primary 4.9% 5.2% 0.95 (0.81-1.11) NSS
![Page 39: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/39.jpg)
Trial Conclusion•In the HOPE-3 trial, treatment with fixed doses of rosuvastatin and two antihypertensive agents was associated with a significantly lower risk of CV events than the risk with placebo among intermediate-risk persons without previous CVD.
NEJM 2016. 374(21):2032-2343
![Page 40: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/40.jpg)
Critical AppraisalStrengths Weaknesses
Large sample size, multicenter Low doses of candesartan/HCLZRandomized, double-blind, double-dummy Adherence rate at end of trial ~75%Intention to treat analysis No benefit shown in candesartan/HCTZ
alone groupLong duration of follow-up No change in mortalityPatient important primary outcome
NEJM 2016. 374(21):2032-2343http://cdn.nejm.org/pdf/Notable-Articles-2016.pdf
![Page 41: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/41.jpg)
Bottom Line•Statins beneficial for intermediate CV risk patients
![Page 42: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/42.jpg)
With your APA – what would you prescribe?
a) Nothing – no indication to prescribeb) A statinc) A blood pressure agentd) Both a statin and a blood pressure agent
Go to: PollEv.com/morganschult061OR Text “MORGANSCHULT061” to 37607
![Page 43: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/43.jpg)
![Page 44: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/44.jpg)
https://assets.wvholdings.com/1/websites/worldventures_com/blog/images/2014/10-2014/10-08-2014/FollowLeader3-DTL.jpeg
Trial Three: LEADERDiabetes
![Page 45: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/45.jpg)
Case Three•70 year old male admitted to family medicine with hyperglycemia
•BG >20mmol/L last 2 days PTA
•Had a cold x 5 days & missed diabetic medication last 3 days
•Home medications restarted• fasting BG now 9-12 mmol/L
•A1c 8% (drawn on admission)
•Attending physician would like to add a GLP-1 analogue
Condition Home MedicationsTD2M Metformin 1000mg PO bid
Gliclazide MR 60mg PO dailyHTN Bisoprolol 5mg PO daily
Ramipril 5mg PO dailyDyslipidemia Atorvastatin 40mg PO dailyCAD (revascularization 5 years ago)
Asa 81mg PO daily
BPH Tamsulosin CR 0.4mg PO daily
![Page 46: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/46.jpg)
Given the patient’s history of CAD, how concerned are you about starting a GLP-1 analogue?
a) Not concerned at allb) Somewhat concernedc) Very concernedd) Would never use a GLP-1 analogue in this populatione) Unsure
Go to: PollEv.com/morganschult061OR Text “MORGANSCHULT061” to 37607
![Page 47: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/47.jpg)
![Page 48: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/48.jpg)
Background•FDA mandates all new antidiabetic therapies for T2DM prove that they will not result in an unacceptable increase in cardiovascular risk•Previous trials with GLP-1 agonists:• ELIXA (lixisenatide) non-inferior to placebo for major adverse
cardiac events• Numerous other trials ongoing
N Engl J Med 2015; 373:2247-2257RxFileshttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
![Page 49: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/49.jpg)
Can J Diabetes 40 (2016) 484–486
![Page 50: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/50.jpg)
N Engl J Med 2016; 375:311-322
Multicenter, double blind, placebo controlled, non-inferiority trial
![Page 51: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/51.jpg)
LEADER: Inclusion & ExclusionInclusion Criteria Exclusion Criteria
T2DM with A1c ≥7% Type 1 DiabetesAge ≥50 & least one CV condition:CHD, CVD, PVD, CKD stage 3 or more, CHF NYHA 2-3
GLP-1 receptor agonists, DPP-4 inhibitors, pramlinitide, rapid-acting insulin
Age ≥60 & at least one CV risk factor:Microalbuminuria, proteinuria, HTN & LVH, left ventricular systolic or diastolic dysfunction, ABI <0.9
Familial/personal history of endocrine neoplasia type 2 or medullary thyroid cancer
ACS, acute cerebrovascular event within 14 days of screening & randomization
N Engl J Med 2016; 375:311-322
![Page 52: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/52.jpg)
LEADER: Baseline Characteristics•N = 9,340
•64 years of age
•64% male
•Mean duration of diabetes: 12.8 years• A1c 8.7%
•81.3% had established CVD
•CKD 24.7%
•Both CVD and CKD 15.8%
N Engl J Med 2016; 375:311-322
![Page 53: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/53.jpg)
Baseline CV and anti-diabetic Medication
Medication Liraglutide (N=4668) Placebo (N=4672)
Beta Blockers 56.8% 54.1%ACE inhibitors 51.8% 50.3%Diuretics 41.8% 41.8%Statins 72.9% 71.4%ASA 63.8% 66.8%Metformin 75.8% 77.1%Sulfonylureas 50.8% 50.6%No insulin treatment 56.3% 54.5%Long acting insulin 22.3% 23.1%Short acting insulin 0.9% 0.6%
N Engl J Med 2016; 375:311-322
![Page 54: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/54.jpg)
N Engl J Med 2016; 375:311-322
![Page 55: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/55.jpg)
LEADER: OutcomesOutcome DescriptorPrimary (composite)
Death from CV causes, nonfatal MI, or nonfatal stroke
Exploratory • Above + coronary revascularization, hospitalization for unstable angina or heart failure
• Death from any cause• Composite of renal/retinal microvascular outcomes• Neoplasms• Pancreatitis
N Engl J Med 2016; 375:311-322
![Page 56: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/56.jpg)
LEADER: Primary Outcome
•Non-inferiority margin set at 1.30
•Non-inferior & superior in both PP & mITT
N Engl J Med 2016; 375:311-322
Outcome Liraglutide Placebo HR (95% CI) NNT (3.8 years)
Primary 13% 14.9% 0.87 (0.78-0.97) p< 0.001 53
![Page 57: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/57.jpg)
N Engl J Med 2016; 375:311-322
![Page 58: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/58.jpg)
LEADER: Glycemic Control•Neither group achieved A1c < 7%
•Mean difference between liraglutidegroup and placebo group in change from baseline: -0.40%
•More placebo patients on:• oral antihyperglycemics• sulfonylureas
• insulin
N Engl J Med 2016; 375:311-322
![Page 59: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/59.jpg)
LEADER: Additional Outcomes•Other effects at 3 years:• 2.3 kg more weight loss in liraglutide group• SBP 1.2mmHg lower/DBP 0.6mmHg higher• Heart rate 3 BPM higher in liraglutide group
N Engl J Med 2016; 375:311-322
![Page 60: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/60.jpg)
LEADER: Exploratory Outcomes
N Engl J Med 2016; 375:311-322
Outcome Liraglutide Placebo HR (95% CI) NNT (3.8 years)Expandedcomposite 20.3% 22.7% 0.88 (0.81-0.96)
p= 0.005 42
Death from any cause 8.2% 9.6% 0.85 (0.74-0.97)
p= 0.02 72
Nephropathy 5.7% 7.2% 0.78 (0.67-0.92)p= 0.003 67
![Page 61: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/61.jpg)
Adverse EffectsOutcome Liraglutide PlaceboPancreatic cancer 13 (0.3%) 5 (0.1%)Acute pancreatitis 18 (0.4%) 23 (0.5%)Acute gallstone disease 145 (3.1%) 90 (1.9%)Leading to discontinuation:Nausea 77 (1.6%) 18 (0.4%)Vomiting 31 (0.7%) 2 (<0.1%)Diarrhea 27 (0.6%) 5 (0.1%)
N Engl J Med 2016; 375:311-322
![Page 62: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/62.jpg)
Trial Conclusion•Among patients with type 2 diabetes who were at high risk for cardiovascular events while they were taking standard therapy, those in the liraglutide group had lower rates of cardiovascular events and death from any cause than did those in the placebo group.
N Engl J Med 2016; 375:311-322
![Page 63: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/63.jpg)
Critical AppraisalStrengths Weaknesses
Large sample size, multicenter Analyzed ITT first, then per protocolRandomized, double-blind, placebo-controlled New drug, too early to know all long term effects
Long duration of follow-up Funded by drug manufacturer
Patient important primary outcome Too short of a study to assess microvascular outcomes
First trial in this drug class to showsuperiority in CV outcome results
First trial in this drug class to show superiority in CV outcome results
RxFilesN Engl J Med 2016; 375:311-322
![Page 64: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/64.jpg)
Other GLP-1 analogue Trials•ELIXA (lixisenatide) non-inferior to placebo for major adverse cardiac events•SUSTAIN-6 (semaglutide) superior to placebo for major adverse cardiac events
N Engl J Med 2015; 373:2247-2257N Engl J Med 2016; 375:1834-1844
![Page 65: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/65.jpg)
Bottom Line•CV benefit! – but lack of coverage currently an issue
![Page 66: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/66.jpg)
Given the patient’s history of CAD, how concerned are you about starting a GLP-1 analogue?
a) Not concerned at allb) Somewhat concernedc) Very concernedd) Would never use a GLP-1 analogue in this populatione) Unsure
Go to: PollEv.com/morganschult061OR Text “MORGANSCHULT061” to 37607
![Page 67: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/67.jpg)
![Page 68: Key Clinical trials of 2016 - Canadian Society of Hospital …cshp.ca/sites/default/files/files/Events/Banff 2017/Key... · RxFiles N Engl J Med 2015;373:2103-16. N Engl J Med 2000;342:145-53.](https://reader033.fdocuments.us/reader033/viewer/2022060712/6078dad274eb7c0fe31983a3/html5/thumbnails/68.jpg)
Acknowledgements•Dr. Jill Hall
•Mr. Vincent Ha
•Misericordia Staff Pharmacists